Estudios originales
Published on 25 de octubre de 2022 | http://doi.org/10.5867/medwave.2022.09.2581
Epidemiological and clinical characteristics of survivors of SARS-COV-2 infection: A descriptive study
Back to article
Persistence of symptoms according to weeks elapsed since the disease.
| Variable | 1 to 4 weeks | 5 to 12 weeks | > 12 weeks | p |
| Age - Mean (SD) (range) | 39.5 (12.4) (20 to 66) | 39.6 (14.0) (18 to 78) | 39.4 (14.0) (18 to 89) | |
| 18 to 29 | 10 (23.3) | 77 (29.8) | 438 (30.4) | |
| 30 to 64 | 32 (74.4) | 166 (64.3) | 939 (65.1) | |
| ≥ 65 | 1 (2.3) | 15 (5.8) | 66 (4.6) | |
| Male | 15 (32.6) | 71 (26.5) | 415 (27.1) | |
| Female | 31 (67.4) | 197 (73.5) | 1117 (72.9) | |
| Asthenia | 19 (41.3) | 128 (46.9) | 587 (38.1) | χ2 = 7.483; p=0.024 |
| Fever | 2 (4.3) | 1 (0.4) | 7 (0.5) | χ2 = 12.822; p=0.002 |
| Odynophagia | 2 (4.3) | 20 (7.3) | 121 (7.9) | χ2 = 0.838; p=0.658 |
| Dorsalgia | 8 (17.4) | 49 (17.9) | 224 (14.6) | χ2 = 2.269; p=0.322 |
| Arthralgias | 6 (13.0) | 54 (19.8) | 231 (15.0) | χ2 = 4.240; p=0.120 |
| Dyspnea | 5 (10.9) | 46 (16.8) | 229 (14.9) | χ2 = 1.353; p=0.508 |
| Headache | 15 (32.6) | 52 (19.0) | 303 (19.7) | χ2 = 4.826; p=0.090 |
| Anosmia/dysosmia | 10 (21.7) | 78 (28.6) | 361 (23.5) | χ2 = 3.461; p=0.177 |
| Ageusia/dysgeusia | 13 (28.3) | 57 (20.9) | 240 (15.6) | χ2 = 9.205; p=0.010 |
| Chest pain | 6 (13.0) | 28 (10.3) | 101 (6.6) | χ2 = 7.032; p=0.030 |
| Rhinitis/nasal congestion | 1 (2.2) | 12 (4.4) | 22 (1.4) | χ2 = 11.059; p=0.004 |
| Cough | 2 (4.3) | 9 (3.3) | 26 (1.7) | χ2 = 4.411; p=0.110 |
| Diarrhea | 1 (2.2) | 14 (5.1) | 52 (3.4) | χ2 = 2.320; p=0.314 |
| Dizziness | 2 (4.3) | 17 (6.2) | 74 (4.8) | χ2 = 1.025; p=0.599 |
| Myalgias | 7 (15.2) | 52 (19.0) | 232 (15.1) | χ2 = 2.778; p=0.249 |
| Vertigo | 0 | 1 (0.4) | 10 (0.6) | χ2 = 0.598; p=0.742 |
| Hyporexia | 2 (4.3) | 8 (2.9) | 35 (2.3) | χ2 = 1.163; p=0.559 |
| Nausea | 0 | 1 (0.4) | 5 (0.3) | χ2 = 0.165; p=0.921 |
| Vomiting | 0 | 1 (0.4) | 1 (0.1) | χ2 = 2.009; p=0.486 |
| Heartburn | 3 (6.5) | 15 (5.5) | 89 (5.8) | χ2 = 0.086; p=0.958 |
| Sweating | 0 | 4 (1.5) | 11 (0.7) | χ2 = 2.015; p=0.365 |
| Concentration/memory disorder | 10 (21.7) | 59 (21.6) | 413 (26.8) | χ2 = 3.727; p=0.155 |
| Anxiety | 5 (10.9) | 53 (19.4) | 326 (21.2) | χ2 = 3.204; p=0.201 |
| Hair loss | 2 (4.3) | 30 (11.0) | 287 (18.6) | χ2 = 15.017; p=0.001 |
| Dysphonia | 5 (10.9) | 27 (9.9) | 124 (8.1) | χ2 = 1.388; p=0.500 |
| Dry mouth | 7 (15.2) | 35 (12.8) | 165 (10.7) | χ2 = 1.824; p=0.402 |
| Tinnitus | 0 | 1 (0.4) | 9 (0.6) | χ2 = 0.462; p=0.794 |
| Sleep disorders | 9 (19.6) | 78 (28.6) | 374 (24.3) | χ2 = 2.962; p=0.227 |
| Ovarian pain | 0 | 3 (1.1) | 11 (0.7) | χ2 = 0.816; p=0.665 |
| Testicular pain | 0 | 0 | 2 (0.1) | χ2 = 0.415; p=0.813 |
| Menstrual disorders | 0 | 8 (2.9) | 22 (1.4) | χ2 = 4.062; p=0.131 |
| Palpitations/Tachycardia | 0 | 1 (0.4) | 4 (0.3) | χ2 = 0.225; p=0.894 |
| Visual impairment | 1 (2.2) | 7 (2.6) | 49 (3.2) | χ2 = 0.426; p=0.808 |
| Dry eyes | 4 (8.7) | 9 (3.3) | 30 (1.9) | χ2 = 10.358; p=.006 |
Source: Prepared by the authors of this study.